Company: INDP
Filing Date: 2025-03-13
Form Type: 10-K
Source: 0001493152-25-010136
Chunk: 361

Company: Indaptus Therapeutics, Inc.
Filing Date: 2025-03-13
Form: 10-K
Item: Item 1B
Chunk 361
---
 Kineticos
Ventures, a firm providing advisory services and capital to emerging life sciences firms. Prior to these positions, between November
2013 and January 2020, Dr. Gilbert was the Chief Medical Officer of Juno Therapeutics Inc., a biopharmaceutical company, where he led
the clinical development of some of the first CAR-T cell therapies. Before that, Dr. Gilbert held leadership positions at Bayer Schering
Pharma AG, where he served as Vice President and Head of Global Clinical Development, Therapeutic Area Oncology; Berlex Pharmaceuticals,
Inc., where he served as Vice President of Medical Affairs, Oncology, and Vice President and Head of Global Medical Development Group,
Oncology; and Immunex Corporation, where he served as Senior Medical Director, Clinical Research and Development. Between May 2019
and May 2021, Dr. Gilbert served as an Independent Director of Silicon Therapeutics, Inc., a fully integrated drug design and development
company. Dr. Gilbert earned a Bachelor of Science degree in Biochemistry from the University of Iowa and a Medical Doctor degree from
the University of Iowa College of Medicine. He trained in internal medicine, infectious disease and medical oncology at the University
of California, San Francisco, and the University of Washington, respectively. We believe Dr. Gilbert is qualified to serve on our board
of directors because of his significant scientific and executive in drug development and in the pharmaceutical industry.

75

Robert
E. Martell, M.D., Ph.D. has served on our board of directors since February 2023. Dr. Martell brings more than 20 years of experience
in the pharmaceutical industry. Dr. Martell is Chief Scientific Officer at Curis, having previously served as Head of Research &
Development. From September 2011 to May 2018, Dr. Martell served on Curis’ Board of Directors. He is also co-founder of Epi-Cure
Pharmaceuticals, a privately held early-stage biotechnology company, and served as its president and member of board of directors from
2016 to 2018. Dr. Martell served as Chief Medical Officer of Tesaro, Inc., a biopharmaceutical company developing Zejula and Varubi from
2012 to 2015; as Chief Medical Officer at MethylGene, a publicly traded biopharmaceutical focused on cancer therapeutics from 2005 to
2009; as Director of Oncology Global Clinical Research at Bristol-My